ASCRS

Oculis Reports Q1 2024 Financial Results and Provides Company Updates

Retrieved on: 
onsdag, maj 8, 2024
Dexamethasone, Pain, State, Inflammation, Investment, Refractive surgery, Safety, NDA, OCS, Research, Cataract, DED, AON, Development, IND, Retina, ASCRS, Research and development, Patient, Society, Pharming, CHF, Genotype, DME, Bank statement, Clinical trial, Annual general meeting, Ophthalmology, Pharmaceutical industry

The two ongoing Phase 3 52-week trials, DIAMOND-1 and DIAMOND-2, started as planned in December 2023 and February 2024, respectively.

Key Points: 
  • The two ongoing Phase 3 52-week trials, DIAMOND-1 and DIAMOND-2, started as planned in December 2023 and February 2024, respectively.
  • Concurrently, the Company listed on the Nasdaq Iceland Main Market in addition to Nasdaq Global Market in the U.S.
    Snehal Shah, Pharm.
  • The Company also aims to complete an IND submission for OCS-05 in the U.S. in 2024.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.

STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision

Retrieved on: 
tisdag, maj 7, 2024
Optical, Health, Surgery, Medical Devices, Education, Near-sightedness, Left, Presbyopia, EVO, Refractive surgery, Cataract, PIB, STAAR, Surgeon, Nave, MD, Quality, ICL, Contact, Chairperson, Lens, ASCRS, Eye, Society, Athlete, Multimedia, Marketing, SMILE, Astigmatism, Growth, Telescopic sight

View the full release here: https://www.businesswire.com/news/home/20240507036972/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240507036972/en/
    Tom Frinzi, Chair of the Board, President and CEO, STAAR Surgical (Left) and Dr. Robert T. Lin, founder and surgeon, IQ Laser Vision (Right).
  • (Photo: Business Wire)
    IQ Laser Vision will make EVO ICL lenses a primary option for patients seeking surgical vision correction within the range of -3D to -20D, as part of its comprehensive refractive offering.
  • IQ Laser Vision intends to nearly double its volume in EVO ICLs over the course of the next 12 months.
  • Today, we’re thrilled to announce that IQ Laser Vision has joined our U.S. Highway 93 program with the largest agreement for EVO ICL in the U.S. thus far.

MYRA VISION'S CALIBREYE™ TITRATABLE GLAUCOMA THERAPY™ SURGICAL SYSTEM SHOWCASED AT OPHTHALMOLOGY CONFERENCES, RECEIVING BEST PAPER AWARD AND RECOGNITION OF FUTURE PROMISE IN GLAUCOMA CARE

Retrieved on: 
onsdag, maj 1, 2024
Glaucoma surgery, Sale, University, Moran Eye Center, Lecture, TGT, Refractive surgery, Hospital, Safety, Research, Cataract, Paratriathlon, IOP, Manchester Royal Eye Hospital, NCT, Biomaterial, ASCRS, Intraocular pressure, Patient, Society, Physician, ICGS, EGS, Glaucoma, Trabeculectomy, Moorfields Eye Hospital, ARVO, Medical device

Dr. De Francesco was awarded best paper of the session, underscoring the tremendous potential of Myra Vision's Calibreye shunt for glaucoma care.

Key Points: 
  • Dr. De Francesco was awarded best paper of the session, underscoring the tremendous potential of Myra Vision's Calibreye shunt for glaucoma care.
  • The Calibreye shunt is designed to deliver an adjustable solution to control IOP in patients requiring low IOP.
  • While these devices have demonstrated an improvement in complication rates, achieving the IOP reductions necessary for these glaucoma patients remains challenging.
  • The Calibreye™ Titratable Glaucoma Therapy™ (TGT) Surgical System is for investigational use only and is not for sale in the U.S. or outside the U.S.

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Retrieved on: 
lördag, april 6, 2024
IOP, Glaucoma, Conditional sentence, Ocular hypertension, Endothelium, Arm, Medicine, Safety, Risk, ASCRS, Patient, Protocol, MD, Genetically modified bacteria, Science, Intraocular pressure, Travoprost, FDA

BEDFORD, Mass., April 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced positive Phase 2 data for PAXTRAVA (travoprost intracameral implant or OTX-TIC) in patients with open-angle glaucoma or ocular hypertension (reported together as “glaucoma”, below) The data are being presented by Mark Gallardo, MD during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.

Key Points: 
  • “Ocular is very pleased to report positive six-month topline results for PAXTRAVA in the Phase 2 glaucoma study.
  • We designed the Phase 2 clinical trial to evaluate PAXTRAVA over several time points that we believe are clinically meaningful, through six months.
  • Most ocular AEs within 3 days were deemed related to the injection procedure by the investigators.
  • I am enthusiastic about PAXTRAVA because of the positive, durable IOP reductions, accompanied by a good overall safety profile,” said Mark Gallardo, MD.

RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting

Retrieved on: 
torsdag, april 4, 2024
Level 3, Refractive surgery, ASCRS, BCEC, Patient, Level 2, EDT, Cataract, Society, Lens, LAL, Telescopic sight

The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+).

Key Points: 
  • The company now offers two lenses in the Light Adjustable Lens platform: the LAL® and the Light Adjustable Lens+™ (LAL+).
  • In addition, RxSight’s Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL/LAL+), RxSight Light Delivery Device (LDD™) and accessories, will be the subject of various doctor presentations at the annual meeting of the American Society of Cataract and Refractive Surgery (ASCRS) in Boston on April 5-8, 2024.
  • At this year's ASCRS meeting, the company anticipates more than 20 scientific papers, posters, and presentations on the topic of the Light Adjustable Lens, including:
    Benefits of Performing Arcuate Incisions with a Dual-Pulsed Femtosecond Laser on Patients Receiving a Light Adjustable Lens.
  • A schedule of these presentations, which are not affiliated with the official ASCRS program, is available here and at the company’s booth throughout ASCRS.

Verana Health Developing Qdata® Dry Eye Disease, the Largest Real-World Dataset of its Kind

Retrieved on: 
torsdag, april 4, 2024
Prevalence, Dry eye syndrome, ASCRS, SAN, Patient, Ophthalmology, Research, RWD, American Academy, Cataract, DED, Society, Data, Telecanthus, Health, Annual general meeting, Nursing

Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.

Key Points: 
  • Qdata DED represents a significant advancement in ophthalmology research, and is the largest of its kind, featuring an extensive dataset that will include outcomes and clinical information on more than 10 million de-identified patients with DED and related ocular conditions.
  • “We’re harnessing the power of real-world evidence to transform patient care and expedite the development of crucial therapies,” said Sujay Jadhav, CEO of Verana Health.
  • Dry eye disease affects nearly 16 million Americans , posing significant challenges for patients and ophthalmologists alike.
  • Verana Health remains at the forefront of this transformation, continuously expanding its Qdata offerings to meet the growing needs of life sciences teams and clinicians.

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Retrieved on: 
onsdag, april 3, 2024
Clobetasol, Exchange, Infection, Acceleration, Refractive surgery, Inflammation, Annual general meeting, ASCRS, Patient, Private practice, Cataract, Society, Ophthalmology

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the company will be conducting demonstrations of its portfolio of commercial products at two upcoming ophthalmology medical meetings.

Key Points: 
  • “Our presence at national medical and commercial meetings like these are key to elevating awareness of our continuum of office-based and surgical products,” stated Michael Rowe, Eyenovia’s Chief Executive Officer.
  • These meetings complement the efforts of our field sales force in amplifying the synergistic nature of our product portfolio as well as the many benefits conferred to doctors and patients by the Optejet device.
  • Eyenovia will also be demonstrating Avenova and reviewing now-approved data on clobetasol, which complements the company’s surgical suite of products.
  • The event features continuing education, keynote speakers, Exchange-only pricing from more than 100 vendors, and opportunities to network with colleagues.

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
tisdag, april 2, 2024
IOP, Gland, Signs, Ciclosporin, Glaucoma, LHT, Wills Eye Hospital, ASCRS, BCEC, Patient, Telecanthus, Meibomian gland dysfunction, Doctor of Philosophy, MD, GEMINI, DED, OMNI, Signs and symptoms, Safety, Poster, Pharmaceutical industry

MENLO PARK, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, announced today that data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System (“OMNI”) and the TearCare System (“TearCare”), will be presented in two oral presentations and two posters at this year’s ASCRS Annual meeting April 5th to 8th in Boston, MA.

Key Points: 
  • OMNI technology facilitates surgeons’ ability to perform a comprehensive, implant-free, minimally invasive glaucoma surgical procedure in adults with primary open-angle glaucoma (“POAG”).
  • Lead author: Julio Echegoyen, MD, PhD
    Localized Heat Therapy (LHT) Compared to Cyclosporine Ophthalmic Emulsion (CsA): A Subanalysis on Age, Gender, and Disease Burden (SAHARA subanalysis) – poster presentation.
  • The event will be on Saturday, April 6, 2024, from 3:45 PM to 4:30 PM ET.
  • Learn more about this and other Sight Sciences activities at ASCRS at www.sightsciences.com/ascrs

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

Retrieved on: 
tisdag, april 2, 2024
NCP, Refractive surgery, ASCRS, Cataract, DED, Society, Pain, Telecanthus, FDA, Annual general meeting

LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.

Key Points: 
  • LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.

SpyGlass Pharma Unveils Compelling 1-Year Data of Its Innovative Drug Delivery Platform Implanted During Routine Cataract Surgery in Eyes with Glaucoma

Retrieved on: 
tisdag, april 2, 2024
IOP, Bimatoprost, Glaucoma, Ocular hypertension, Pressure, IOL, ASCRS, Patient, Tissue, Cataract, Month, Spyglass, Visual acuity, Society, Safety, IOPS, Therapy, FDA, Intraocular pressure, Annual general meeting, Pharmaceutical industry

ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery. These data will be highlighted in a poster presentation during the American Society of Cataract and Refractive Surgeons (ASCRS) Annual Meeting, held from April 5-8 in Boston.

Key Points: 
  • ALISO VIEJO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately-held ophthalmic biotechnology company, announced today 1-year follow up data from a first-in-human study of 23 patients with glaucoma or ocular hypertension implanted with SpyGlass’ Intraocular Lens (IOL) based Drug Delivery Platform with bimatoprost at the time of cataract surgery.
  • The SpyGlass platform was well tolerated and there were no adverse events related to the product.
  • These data highlight the substantial potential of the SpyGlass Drug Delivery Platform to be a game changer for patients and all cataract surgeons.”
    “SpyGlass technology has the potential to change the paradigm and improve care for glaucoma patients undergoing routine cataract surgery,” said Patrick Mooney, CEO, SpyGlass PharmaTM.
  • The compelling clinical data released this week suggest we are on track to bringing our innovative platform to patients.”
    The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver 3 years of bimatoprost to targeted tissues.